Medicine safety is in focus as the iDexis court case raises questions about compounding, regulation and patient monitoring. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
iDexis semaglutide ban stops the pharmacy group from selling compounded weight-loss medicines while SAHPRA and the SAPC investigate. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
The Semaglutide Compounding Dispute intensifies as Novo Nordisk takes iDexis to court over illegal manufacturing of weight-loss injections. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
Compounded GLP-1 injections are at the centre of a regulatory dispute. iDexis challenges SAHPRA and SAPC recall orders. Subscription Required You must be a subscriber to access all of this content. View Subscriptions Already a subscriber? Log in...
